Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q2 EPS of ($0.45), in-line with the analyst estimate of ($0.45). Revenue for the quarter came in at $161.6 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
• Rekor Systems, Inc. (REKR) Tops Q2 EPS by 3c